Accession Therapeutics

Accession Therapeutics is an emerging private biotech company pioneering a differentiated approach in immuno-oncology with its Trocept platform, a stealth virus technology engineered for tumor-specific entry. The company has advanced its lead candidate, TROCEPT-01 (ATTR-01), into a Phase 1 trial (ATTEST) for solid cancers and is building a broader pipeline. Backed by significant recent funding and led by an experienced team, including immuno-oncology pioneer Bent Jakobsen, Accession is positioning itself to address the limitations of current immunotherapies.

Trocept stealth virus platform: an engineered viral vector platform designed for tumor-specific entry and activation, bypassing healthy cells to deliver therapeutic payloads and address tumor heterogeneity.

Accession competes in the broad and competitive oncolytic virus and tumor-targeted therapy space, which includes companies like Replimune, Turnstone Biologics, and DNAtrix. Its key claimed differentiator is the engineered specificity of viral entry to cancer cells only.